Colomer Bosch, Ramon ramon.colomer@uam.es
Actividades
- Artículos 257
- Libros 4
- Capítulos de libro 3
- Congresos 91
- Documentos de trabajo 1
- Informes técnicos 4
- Proyectos de investigación 1
- Tesis dirigidas 9
- Patentes o licencias de software 0
F-18-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
- Quintela-Fandino, M.
- Lluch, A.
- Manso, L.
- Calvo, I.
- Cortes, J.
- García-Saenz, J.A.
- Gil-Gil, M.
- Martinez-Jánez, N.
- Gonzalez-Martin, A.
- Adrover, E.
- De Andres, R.
- Viñas, G.
- Llombart-Cussac, A.
- Alba, E.
- Guerra, J.
- Bermejo, B.
- Zamora, E.
- Moreno-Anton, F.
- Simon, S.P.
- Carrato, A.
- Lopez-Alonso, A.
- Escudero, M.J.
- Campo, R.
- Carrasco, E.
- Palacios, J.
- Mulero, F.
- Colomer, R.
Clinical Cancer Research (p. 1432-1441) - 15/3/2017
Editor: American Association for Cancer Research Inc.
10.1158/1078-0432.ccr-16-0738 Ver en origen
- ISSN 15573265
- ISSN/ISBN 1557-3265
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
- Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ
Breast Cancer Research (p. 21-21) - 1/12/2021
- ISSN 14655411
- iMarina
Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
- Puig, Teresa
- Vazquez-Martin, Alejandro
- Relat, Joana
- Petriz, Jordi
- Menendez, Javier A.
- Porta, Rut
- Casals, Gemma
- Marrero, Pedro F.
- Haro, Diego
- Brunet, Joan
- Colomer, Ramon;
Breast Cancer Research And Treatment (p. 471-479) - 1/6/2008
- ISSN 01676806
- iMarina
Fatty acid metabolism in cancer cells: Differential inhibitory effects of epigallocatechin (EGCG) and C75
- Teresa Puig
- Alejandro Vázquez-Martín
- Pedro Marrero
- Gemma Casals
- Jordi Pétriz
- Joana Relat
- Diego Haro
- Javier A Menéndez
- María Luz López-Rodríguez
- Maria Vilanova
- Ramon Colomer
Clinical Cancer Research (p. B28-B28) - 1/1/2006
- ISSN 15573265
- iMarina
Fatty acid synthase: a new anti-tumor target
- Teresa Puig
- Rut Porta
- Ramon Colomer
Medicina Clinica (p. 359-363) - 14/3/2009
- ISSN 00257753
- iMarina
Favorable prognosis after late relapse of Hodgkin's disease
- GarciaCarbonero, R
- Arcediano, A
- PazAres, C
- Lahuerta, J
- Colomer, R
- CortesFunes, H;
European Journal Of Cancer (p. 560-565) - 1/1/1998
- ISSN 09598049
- iMarina
Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia
- Sureda A., Isla D., Cózar J.M., Ruiz M., Domine M., Margelí M., Adrover E., Ramos M., Pastor M., Martín A., Llombart A., Massuti B., Muñoz M., Barnadas A., Fernández J., Colomer R., Allepuz C., Gilabert M., Badia X.
Journal Of Medical Economics (p. 27-39) - 1/1/2007
10.3111/200710027039 Ver en origen
- ISSN 1941837X
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga JY, Jung KH, Schem C, Hogea A, Badovinac Crnjevic T, Heeson S, Shivhare M, Kirschbrown WP, Restuccia E, Jackisch C, FeDeriCa study group
Lancet Oncology (p. 85-97) - 1/1/2021
10.1016/s1470-2045(20)30536-2 Ver en origen
- ISSN 14702045
Gemcitabine and paclitaxel in metastatic breast cancer: a review
- Colomer R
Oncology (p. 8-12) - 1/1/2004
- ISSN 00302414
- iMarina
Adding pertuzumab in neoadjuvant treatment of patients with HER2 (+) breast cancer in Spain: A cost offsets study
- J Albanell
- E Ciruelos
- R Colomer
- J De la Haba
- M Martin
- De Salas-Cansado
- B Munoz-Molina
- C Tournier
- P Thuresson
- W Schleich
1/1/2015
- iMarina
Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
- J Rogado
- MD Fenor De La Maza
- V Pacheco-Barcia
- JM Serra
- P Toquero
- B Vera
- A Ballesteros
- R Mondejar
- O Donnay
- B Obispo
- R Colomer
- JM Sanchez-Torres
1/1/2017
- iMarina
Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated …
- Chau Dang
- Michael S Ewer
- Suzette Delaloge
- Jean-Marc Ferrero
- Mark Verrill
- Ramon Colomer
- Claudia Vieira
- Luis de la Cruz Merino
- Jennifer Lucas
- Theresa L Werner
- Hannah Douthwaite
- Denise Bradley
- Maeve Waldron-Lynch
- Jennifer Eng-Wong
- Sandra M Swain
1/1/2018
- iMarina
Fatty acid metabolism in cancer cell survival: A new anti-cancer target
- Porta, Rut
- Colomer, Ramon
- Puig, Teresa;
Cell Respiration And Cell Survival: Processes, Types And Effects (p. 193-208) - 1/12/2011
- iMarina
Medicina de precisión en oncología: Éxitos y perspectivas bioéticas
- Ramón Colomer Bosch
Bioética Y Cáncer (p. 17-26) - 1/1/2020
- iMarina
18F-misonidazole PET (FMISO-PET) monitors vascular normalization (VN) and predicts benefit from antiangiogenic treatment plus chemotherapy in pancreas cancer
- Mondejar, Tamara
- Hernadez-Agudo, Elena
- Soto-Montenegro, Marisa
- Megias, Diego
- Cebrian, David
- Sanchez, Jesus
- Mulero, Francisca
- Colomer, Ramon
- Hidalgo, Manuel
- Desco, Manuel
- Quintela-Fandino, Miguel;
Cancer Research - 1/1/2015
10.1158/1538-7445.am2015-1493 Ver en origen
- ISSN 00085472
A decade of clinical investigation in elderly patients with non-Hodgkin's lymphoma: Results as reported in the literature
- Gomez, H
- Colomer, R
- Casttellanos, D
- CortesFunes, H;
European Journal Of Cancer (p. 1205-1205) - 1/1/1997
- ISSN 09598049
- iMarina
ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2(+) BREAST CANCER IN SPAIN: A COST OFFSETS STUDY
- Albanell, J.
- Ciruelos, E.
- Colomer, R.
- De la Haba, J.
- Martin, M.
- De Salas-Cansado, M.
- Munoz-Molina, B.
- Tournier, C.
- Thuresson, P.
- Schleich, W.;MORSE Hlth Technology Assessment
- Global Pricing Market Access
Basic & Clinical Pharmacology & Toxicology (p. 42-42) - 1/1/2015
- ISSN 17427835
- iMarina
An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations
- B Leyland-Jones
- R Colomer
- M Trudeau
- A Wardley
- J Latreille
- D Cameron
- R Cubedo
- N Al-Sakaff
- JE Charoin
- J Cortés
European Journal Of Cancer, Supplement (p. 215-215) - 1/1/2007
10.1016/s1359-6349(07)70867-4 Ver en origen
- ISSN 13596349
- iMarina
- iMarina
Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
- J Rogado
- Fenor De La Maza
- V Pacheco-Barcia
- J Serra
- P Toquero
- B Vera
- A Ballesteros
- R Mondéjar
- O Donnay
- B Obispo
- R Colomer
- J Sánchez-Torres
Journal Of Thoracic Oncology (p. S2107-S2108) - 1/1/2017
- ISSN 15560864
- iMarina
Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)
- Rogado Revuelta, Jacobo
- Romero-Laorden, Nuria
- Sanchez Torres, Jose Miguel
- Pacheco-Barcia, Vilma
- Ballesteros, Anabel
- Maria Ramos-Levi, Ana
- Arranz, Reyes
- Lorenzo, Alicia
- Gullon, Pedro
- Garrido Garcia, Ana
- Maria Serra, Jose
- Donnay, Olga
- Adrados, Magdalena
- Costas, Pablo
- Aspa, Javier
- Alfranca, Arantza
- Fenor De la Maza, Maria Dolores
- Mondejar, Rebeca
- Colomer, Ramon;
Journal Of Clinical Oncology - 1/1/2019
- ISSN 0732183X
- iMarina
Breast cancer-Anaemia and the Value of Erythropoietin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30,000 IU once weekly in patients with metastatic breast cancer receiving chemotherapy
- Marangolo, M.
- Lang, I.
- Beato, C.
- Colomer, R.
- Ukarma, L.;
European Journal Of Cancer, Supplement (p. 388-388) - 1/1/2005
- ISSN 13596349
- iMarina
Breast cancer-Anaemia and the Value of Erythropoietin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30,000 IU once weekly in patients with …
- M Marangolo
- I Lang
- C Beato
- R Colomer
- L Ukarma
(p. 388-388) - 1/1/2005
- iMarina
CA 15.3 - A NEW MARKER FOR BREAST-CANCER (BC) PRELIMINARY-RESULTS
- SOLE, LA
- COLOMER, R
- NAVARRO, M
- ENCABO, G
- RUIBAL, A;
Anticancer Research (p. 601-602) - 1/1/1985
- ISSN 02507005
- iMarina
CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN
- Ciruelos, E.
- Alba, E.
- Lopez, R.
- Lluch, A.
- Martin, M.
- Arroyo, I
- Navarro, B.
- Carcedo, D.
- Colomer, R.
- Albanell, J.;
Value In Health (p. S18-S18) - 1/1/2018
10.1016/j.jval.2018.09.102 Ver en origen
- ISSN 10983015
[Generalized cutaneous-nodal metastatic spread as initial manifestation of the recurrence of a gastric adenocarcinoma]
- Sanchez-Munoz, A
- Gravalos Castro, C
- Colomer Bosch, R
- Garcia Velasco, A
- Garcia, J P
- Cortes-Funes, H
Revista Clinica Espanola (p. 597-598) - 1/1/2003
- ISSN 15781860
- iMarina
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer
- Antón A, Hornedo J, Lluch A, Massuti B, Corral M, Colomer R
Clinical Breast Cancer (p. 286-91) - 1/1/2003
10.3816/cbc.2003.n.034 Ver en origen
- ISSN 15268209
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators
Journal Of Clinical Oncology (p. 3987-3998) - 1/12/2020
- ISSN 0732183X
- iMarina
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.
- Hitt, R
- Paz-Ares, L
- Hidalgo, M
- Colomer, R
- Brandariz, A
- Pena, M
- Alvarez-Vicent, J
- Hornedo, J
- Cortes-Funes, H;
Seminars In Oncology (p. S19-20) - 1/12/1997
- ISSN 00937754
- iMarina
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization
- Arranz, R.
- García-Alfonso, P.
- Sobrino, P.
- Zamora, P.
- Carrión, R.
- García-Laraña, J.
- Pérez, G.
- López, J.
- Lavilla, E.
- Lozano, M.
- Rayón, C.
- Colomer, R.
- González Barón, M.
- Flores, E.
- Pérez-Manga, G.
- Fernández-Rañada, J.M.
Journal Of Clinical Oncology (p. 1538-1546) - 1/1/1998
Editor: American Society of Clinical Oncology
10.1200/jco.1998.16.4.1538 Ver en origen
- ISSN 0732183X
- ISSN/ISBN 0732-183X
- Dialnet
- iMarina
Cambios en el perfil inmunohistoquímico tras tratamiento neoadyuvante en pacientes con cáncer de mama
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Miguel Martín Giménez (Director) Doctorando: Rebeca Mondéjar Solís
1/1/2016
- iMarina
Características y evolución del cáncer de mama metástásico al diagnóstico: comparación con las recidivas del cáncer de mama inicialmente localizado
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca (Director) Doctorando: Antonio Jimeno Largo
1/1/2003
- iMarina
Efectos de la inhibición de la síntesis de ácidos grasos en la eficacia de los tratamientos antineoplásicos
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Alejandro Vázquez Martín
1/1/2007
- iMarina
El fenotipo basal-her2 en el cáncer de mama: caracterización clínico-molecular e implicaciones terapéuticas
- Colomer Bosch, Ramon (Autor o Coautor)
- Javier Abel Menéndez Menéndez (Director)
- Ramón Colomer Bosch (Director) Doctorando: Begoña Martín Castillo
1/1/2016
- iMarina
Estudio fase i/ii con dosis altas de mitoxantrone y ciclofosfamida sin soporte hematopoyético para el tratamiento de tumores de alto riesgo y metastásicos
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca (Director) Doctorando: José Luis Pérez Gracia
1/1/2004
- iMarina
Importancia de la dosis de antraciclinas en el tratamiento adyuvante del cáncer de mama
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca Lorente (Director) Doctorando: María Luz Amador Muñoz
1/1/2002
- iMarina
Utilidad de la expresión de p53 en tumores de mama como factor pronóstico y predictor de la respuesta al tratamiento
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Cecilia Guzman Zapater
1/1/1996
- iMarina
Ácidos grasos en la progresión del cáncer de mama: implicaciones terapéuticas
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Javier Abel Menéndez Menéndez
1/1/2001
- iMarina
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Publons
-
Scopus Author ID
-
Dialnet id